학술논문
Effects of Denosumab on Bone Mineral Density and Bone Turnover in Postmenopausal Women Transitioning From Alendronate Therapy.
Document Type
Article
Author
Source
Journal of Bone & Mineral Research; Jan2010, Vol. 25 Issue 1, p72-81, 10p, 1 Diagram, 2 Charts, 3 Graphs
Subject
Language
ISSN
08840431
Abstract
The article presents a study which looks at the effects of denosumab on bone mineral density (BMD) and bone turnover in postmenopausal women with osteoporosis. This study involved 504 postmenopausal women with a BMD T-score of -2.0 or less and -4.0 or more who have been receiving alendronate therapy for at least 6 months. The researchers evaluated changes in BMD and biochemical markers of bone turnover. They found that transitioning to denosumab increases BMD and reduces markers of bone turnover to a greater extent than continued alendronate therapy.